Cellular and Humoral Immune Responses after 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant

Research output: Contribution to journalLetterContributedpeer-review

Contributors

Details

Original languageEnglish
Pages (from-to)E267-E269
JournalTransplantation
Volume105
Issue number11
Publication statusPublished - 1 Nov 2021
Peer-reviewedYes

External IDs

PubMed 34342963
ORCID /0000-0003-2739-345X/work/142239599
ORCID /0000-0002-1507-8009/work/142241672
ORCID /0000-0002-9728-1413/work/145699140
ORCID /0000-0003-1875-273X/work/175220416
ORCID /0000-0002-8059-4368/work/175220649
PubMedCentral PMC8549130

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • Adult, Aged, Antibodies, Viral/blood, BNT162 Vaccine, COVID-19/immunology, COVID-19 Vaccines/administration & dosage, Female, Graft Rejection/immunology, Humans, Immunity, Cellular/drug effects, Immunity, Humoral/drug effects, Immunization, Secondary/statistics & numerical data, Immunosuppressive Agents/administration & dosage, Kidney Transplantation/adverse effects, Male, Middle Aged, SARS-CoV-2/immunology, Transplant Recipients/statistics & numerical data